Sight Sciences to Report Third Quarter Financial Results on November 7, 2024
Sight Sciences Reports Publication Of New Study Titled, Impact Of TearCare On Reading Speed In Patients With Dry Eye Disease In The Peer-reviewed Journal Clinical Ophthalmology
Single TearCare Treatment Improved Functional Visual Outcomes as Well as Signs and Symptoms of Patients With Dry Eye Disease in Investigator-Initiated Trial
Don't Ignore The Insider Selling In Sight Sciences
Institutional Investors Own a Significant Stake of 34% in Sight Sciences, Inc. (NASDAQ:SGHT)
Lake Street Maintains Sight Sciences(SGHT.US) With Buy Rating, Maintains Target Price $10
Analysts Are Bullish on These Healthcare Stocks: Bioventus (BVS), Sight Sciences (SGHT)
Morgan Stanley Maintains Sight Sciences(SGHT.US) With Hold Rating, Raises Target Price to $7
Morgan Stanley analyst Kallum Titchmarsh maintains $Sight Sciences(SGHT.US)$ with a hold rating, and adjusts the target price from $5 to $7.According to TipRanks data, the analyst has a success rate
Sight Sciences: A Balanced View Amidst Recovery and Uncertainties
Lake Street Initiates Sight Sciences(SGHT.US) With Buy Rating, Announces Target Price $10
Lake Street analyst Frank Takkinen initiates coverage on $Sight Sciences(SGHT.US)$ with a buy rating, and sets the target price at $10.According to TipRanks data, the analyst has a success rate of 41.
Lake Street Initiates Coverage on Sight Sciences With Buy Rating, $10 Price Target
Sight Sciences Poised for Growth: Buy Rating Affirmed Amid Market Expansion and Favorable Reimbursement Outlook
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference
Sight Sciences, Inc. (SGHT) Q2 2024 Earnings Call Transcript
Sight Sciences | 10-Q: Q2 2024 Earnings Report
Q2 2024 Sight Sciences Inc Earnings Call
Sight Sciences Shares Are Trading Lower After the Company Reported Q2 Financial Results and Narrowed Its FY24 Revenue Guidance Below Estimates.
Morgan Stanley Sticks to Their Hold Rating for Sight Sciences (SGHT)
Sight Sciences (SGHT) Gets a Hold From Piper Sandler
Needham Reiterates Hold on Sight Sciences